Answers are grounded in this paper and cite their sources.
With the advent of symptomatic treatment and the prospect of stabilizing therapies for AD, the race for reliable disease and progression markers has picked up speed. Two hot contenders are described in this issue of Neurology: CSF measures of β-amyloid(1-42) (Aβ-42) and tau levels as diagnostic markers1 and MRI quantification of brain atrophy changes for monitoring progression.2 How good are these biomarkers, and how far away are they from routine use in clinical practice? The desired sensitivity and specificity of a proposed biomarker depends on its purpose: for example, screening at-risk populations, differentiating AD from aging and other dementias, or monitoring progression and therapeutic response.3 One biomarker is unlikely to serve all these purposes. The current “bronze standard” for diagnosis—namely, expert clinical assessment that meets the criteria for probable AD of the National Institute for Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association—uses a combination of history, physical, and cognitive examination, as well as blood tests and neuroimaging, to exclude secondary causes. The diagnostic accuracy achieved in research centers when these criteria are followed is 85% to 90%.4 In “gold standard” …
No takes yet. Share an insight, caveat, or question.
Sandra E. Black (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: